Although the downstream consequences of metabolic reprogramming observed in IDH mutated gliomas are yet to be fully elucidated, the incorporation of IDH status into the WHO diagnostic criteria indicate a significant diagnostic and prognostic role of the genetic abnormality. The gene discussed is IDH1; the disease is central nervous system cancer.